Table 4. Selected CGPs in lumA unfavorable prognosis groups.
| ADAM10 | HES1 | NOTCH1 | NOTCH3 | PSEN1 | |
|---|---|---|---|---|---|
| Doxorubicin resistance | 0.108 | - | 0.001 | 0.007 | - |
| Tamoxifen resistance dn | 0.204 | 0.231 | - | - | - |
| Alkylating agents resistance up | - | - | 0.002 | 0.022 | - |
| Alkylating agents resistance dn | 0.034 | 0.193 | - | - | 0.221 |
| Endocrine therapy resistance | 0.001 | - | 0.25 | 0.156 | - |
| Mitoxantrone resistance | 0.006 | - | 0.033 | 0.108 | - |
| Dasatinib resistance up | 0.232 | - | 0.001 | 0.005 | - |
| Cisplatin resistance up | 0.245 | - | 0.005 | 0.008 | - |
| Sensitivity to fluorouracil | 0.019 | - | 0.023 | 0.191 | - |
| Sensitivity to cyclophosphamide | 0.065 | - | - | - | - |
| Sensitivity to vincristine | 0.231 | - | 0.045 | 0.021 | - |
| CTNNB1 oncogenic signature | 0.000 | 0.15 | 0.082 | 0.214 | - |
| Metastasis up | 0.001 | 0.191 | 0.22 | - | 0.042 |
| Epithelial-to-mesenchymal tansition up | 0.22 | - | 0.000 | 0.000 | - |
| Cancer mesenchymal transition signature | - | - | 0.019 | 0.005 | - |
| Metastasis EMT up | 0.177 | - | 0.063 | 0.029 | - |